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Abstract 33 
 34 
Background:  Flow cytometry (FC) is assuming increasing importance in diagnosis in veterinary oncology. The 35 
European Canine Lymphoma Network (ECLN) is an international cooperation of different institutionsworking on 36 
canine lymphoma diagnosis and therapy. The ECLN panel of experts on FC has defined the issue of reporting FC on 37 
canine lymphoma and leukemia as their first hot topic, since a standardized report that  includes all the important 38 
information is still lacking in veterinary medicine. 39 
 40 
Methods: The flow cytometry panel of the ECLN started a consensus initiative using the Delphi approach. Clinicians 41 
were considered the main target of FC reports. A panel of experts in FC was interrogated about the important 42 
information needed from a report.  43 
 44 
Results: Using the feedback from clinicians and subsequent discussion, a list of information to be included in the report 45 
was made, with four different levels of recommendation. The final report should include both a quantitative part and a 46 
qualitative or descriptive part with interpretation of the salient results. Other items discussed included the necessity of 47 
reporting data regarding the quality of samples, use of absolute numbers of positive cells, cutoff values, the intensity of 48 
fluorescence, and possible aberrant patterns of antigen expression useful from a clinical point of view. 49 
 50 
Conclusion:  The consensus initiative is a first step towards standardization of diagnostic approach to canine 51 
hematopoietic neoplasms among different institutions and countries. This harmonization will improve communication 52 
and patient care and also facilitate the multicenter studies necessary to further our knowledge of canine hematopoietic 53 
neoplasms. 54 
  55 
Flow cytometry (FC) is increasingly being used in veterinary clinical pathology laboratories owing to the increasing 56 
number of FC facilities, greater availability of specific antibodies labeled with different fluorochromes, and the rapidity 57 
with which results can be generated. Immunophenotyping hematopoietic neoplasms is one of the most important 58 
applications of FC in veterinary clinical pathology diagnostics since this method rapidly provides useful information on 59 
the lineage of neoplastic cells, identifies some specific neoplastic subtypes (T zone lymphomas, chronic lymphocytic 60 
leukemia) [1-4], accurately defines stage [5] and, in some cases, can detect minimal residual disease [6]. 61 
 62 
The overall utility of flow cytometry and its role in the diagnostic pathway is dependent on several aspects. One aspect 63 
is the ability to provide important information to frame the neoplastic disease in the context of results of other clinical 64 
and laboratory tests. Therefore, a useful FC report should contain all the appropriate information required by clinicians, 65 
provide improved characterization of the neoplastic disease, help determine therapy, and inform a monitoring strategy 66 
to enable early detection of relapse. This requires sufficient clarity of reporting to allow understanding by non-FC 67 
experts. The specific experience of the flow cytometrist should help in the interpretation of the results, always in 68 
conjunction with signalment, clinical presentation, and the results of other laboratory tests. However, an appropriate 69 
report should also contain all necessary raw data and describe the strategies used to generate them. This provides 70 
information about reproducibility and facilitates interpretation by other experts in second opinion or multicenter 71 
studies. The balance between these two aspects, the clinician-friendly utility and the inclusion of sufficient technical 72 
information to represent a rigorous and reproducible analysis, shapes the format of the FC report. 73 
 74 
In human medicine, the issue of reporting flow cytometry immunophenotyping has been widely debated [7, 8] and 75 
guidelines have been published and regularly updated [9, 10]. Until now, there has been no similar discussion in 76 
veterinary medicine. To the authors' knowledge, every veterinary FC facility uses its own strategy and system in 77 
reporting results of immunophenotyping. 78 
 79 
Methods 80 
 81 
The European Canine Lymphoma Network (ECLN) is a network that was created in 2009 with the aim of establishing 82 
cooperation among different institutions working on canine lymphoma diagnosis and therapy [11]. The definition of 83 
consensus guidelines and approaches is one of the main goals of ECLN and a specific panel on FC has been formed 84 
gathering 16 participants selected on demonstrated expertise in veterinary FC. The ECLN aims to drive the creation of 85 
consensus guidelines, possibly interfacing with extra EU specialists, in a democratic and inclusive way. The FC panel of 86 
the ECLN defined the issue of reporting FC immunophenotyping as the first “hot” topic requiring a consensus 87 
discussion. 88 
 89 
When attempting to reach a consensus on defined topics using online-based surveys, a tool called the Delphi method is 90 
considered the best technique [12]. This method relies on a series of questionnaires provided to the panel participants 91 
in “rounds” until answers converge towards a common answer. Only statements reaching at least 75% consensus 92 
agreement are included in the final document, otherwise statements are re-written and additional rounds of questions 93 
follow until the threshold agreement level of 75% is reached. After review of the results of the explorative survey and 94 
the relevant reference sources, the members of the FC panel are approached through successive rounds of questioning 95 
and the answers and feedback are collected in an anonymous fashion. The statements passing the threshold are finally 96 
considered as common recommendations and contribute to the consensus paper. 97 
 98 
The panel of experts in flow cytometry of the ECLN was also interrogated for each piece of information with four 99 
different levels of recommendation: mandatory, recommended, additional, or irrelevant. Results on the percentage of 100 
agreement are reported in Table 1 (16/16 responders). Relevance of information was based on a 75% response 101 
threshold. If >75% of respondents answered “mandatory”, “recommended,” or “additional” for a specific category 102 
without either response necessarily reaching 75% individually, the category was considered “relevant.” The consensus 103 
level of recommendation was reported if it reached at least 50% of agreement among responders. If agreement was 104 
<50% for any level, the final recommendation was reported as “no consensus.” 105 
 106 
Before starting with the discussion on different issues, the panel of experts in FC decided to document the perceived 107 
needs of clinicians. A preliminary exploratory survey among the members of the ECLN therapy working group, 108 
consisting of clinicians interested in the study and therapy of canine lymphoma, was conducted. The complete results 109 
obtained from this survey are not included in detail in the present document but were used as a starting draft for the 110 
members of the FC panel for discussion in order to define the relevance of each component to be submitted to this 111 
consensus evaluation. 112 
 113 
Results 114 
 115 
Preliminary Exploratory Survey Among the Members of the ECLN Therapy Working Group 116 
 117 
Thirty out of 66 clinicians (45%) of the ECLN therapy working group responded to the preliminary survey. Most (51.7%) 118 
respondents reported requesting FC in >80% of lymphoma cases, and 17.2% of respondents reported requesting FC in 119 
>50% but <80% of lymphoma cases. Only 24.1% of respondents reported the use of FC in <20% of lymphoma cases. 120 
Most respondents (51.7%) also reported sending blood and bone marrow samples for staging in selected cases, while 121 
63.3% stated that they usually add smears from blood, bone marrow or lymph node for concurrent cytomorphologic 122 
evaluation. 123 
 124 
The majority of clinicians (58.6%) reported the definition of the immunophenotype of the neoplasm as the main reason 125 
for requiring FC, while refining lymphoma subtype (20.7%), definition of prognosis (6.9%), checking minimal residual 126 
disease (3.4%) and differentiating lymphoma from reactive conditions (3.4%) were reasons reported less frequently. 127 
 128 
The minimally invasive nature of sampling (40%), the accuracy in resolving reactive vs. neoplastic conditions (16%) and 129 
the rapidity of the results (12%) were recognized as the main advantages of FC over other techniques. The most 130 
important mentioned characteristics required for a flow cytometric report were that they should first be both 131 
exhaustive and accurate (46.4%) and second, easy to read and interpret (42.9%). 132 
 133 
Results were variable among respondents, indicating that the needs of clinicians are quite heterogeneous. However, the 134 
following components were considered to be essential information, with a consensus of >75% of responders: 135 
specification of the type of tissue sent, assessment of the quality of the sample, reliability of documented marker 136 
expression dependent on sample quality, panel of antibodies applied and aberrant patterns identified. All the other 137 
information (the same detailed in Table 1) was generally considered as important or essential (although without 75% 138 
consensus), except specification of the instrument used for analysis, which was considered irrelevant information by 139 
most clinicians. 140 
 141 
Identification of Discussion Topics 142 
 143 
Two major and eight minor issues were identified and subsequently discussed, the discussion including published 144 
sources both in human and veterinary medicine. 145 
 146 
Major issues 147 
 148 
Identification of the “target users and/or recipients” of FC reports and their needs 149 
 150 
The identification of the final “targets” of FC immunophenotyping reporting on canine lymphomas and leukemias is 151 
crucial for appropriately defining the relevant information to be included in the report. 152 
 153 
Three main “target user and/or recipient groups” with different needs were identified: (1) owners, interested in 154 
understanding their pet's disease; (2) clinicians, mainly specialists in oncology, interested in characterizing the disease in 155 
order to define prognosis, target therapy and monitor follow-up; and (3) clinical pathologists, sometimes specialists in 156 
FC, asked to interpret the results of laboratory tests in an integrated way or to provide a second opinion. The relevance 157 
and emphasis of each piece of information provided in the FC report is variable among these three user groups. 158 
 159 
Clinicians were considered the most important target users of FC reports as they decide if the FC analysis is indicated, 160 
provide the samples, communicate the results to owners and institute treatment. 161 
 162 
Pet owners were not considered the major target of FC reports since management by the clinician/oncologist is the 163 
most common situation. They are generally interested in an accurate diagnosis of the disease from which their pet is 164 
suffering. Bibliographic references to support the diagnosis and better clarify the disease biology should be considered 165 
optional items in generating a final report. Mentioning the operator/specialist's name and titles should be included as 166 
well. 167 
 168 
Finally, other specialists such as clinical pathologists and flow cytometrists were considered possible targets of FC 169 
reports. Their needs are generally much more related to technical aspects, such as data on gating strategies, possible 170 
artefactual changes, viability/conservation of the sample, raw percentages (and absolute numbers) of neoplastic cells, 171 
type of labeling used (multicolor vs. monocolor; composition of tubes, antibody clones used), and controls. Possibly 172 
scattergrams could be used to better clarify some of the technical aspects. However, the inclusion of such technical 173 
information in the standard FC report could appear extraneous and lead to confusion of non-experts in FC. This 174 
information should be omitted from the standard FC report but could remain available to be provided upon request, 175 
including, if necessary, raw FCS files. 176 
 177 
Reporting percentages vs. descriptive report 178 
 179 
Percentages and possibly absolute numbers commonly form the basis for FC immunophenotyping. This method is 180 
considered more objective and accurate; however, a series of problems may be encountered: (1) percentages are 181 
directly dependent upon gating strategy (scatter properties vs. CD45 positive cells vs. specific subtypes), (2) percentages 182 
of positive events do not provide any information regarding co-expression, (3) percentage of positivity is highly 183 
dependent on controls used to set cutoff values, (4) providing percentage of positive events alone often cannot 184 
distinguish neoplastic and residual normal cells, and (5) percentages of positive events may be redundant and may not 185 
contribute to clarity and easy interpretation of the results. Reporting percentages of positive events in different cell 186 
subpopulations, identified upon light scatter or immunophenotypic features (for instance high FSC low SSC cells, or 187 
CD21 positive cells) may further improve accuracy of the report. 188 
 189 
In contrast, a descriptive report may better focus on neoplastic cells, is clearer and easier to interpret, avoids 190 
redundancies and may provide information on co-expression, aberrant pattern(s) and quantitative expression. 191 
However, it may be less objective since it is often biased by the interpretation and experience of the specialist. It is 192 
recommended that objective (percentage of positive cells) and subjective (i.e., descriptive interpretation based on 193 
experience) statements be clearly identifiable in the report. The descriptive report should be conversational and may 194 
easily include data from other laboratory tests (cytological review, molecular clonality assessment, CBC, etc). 195 
 196 
Consensus was reached regarding the necessity to include both parts in the FC report, with an emphasis on the 197 
conversational, descriptive part. Data such as the percentages of positive cells should be reported in parentheses or in a 198 
table attached to the written report. Data about cells not considered important for the tumor subtype (for instance 199 
myeloid cells in lymphomas, T cell subsets in B cell neoplasms, residual lymphoid population in AML) should be 200 
reported, but with an effort to clearly identify them as additional information (in the conversional part) in order to 201 
avoid confusion and redundancies. These data could be discussed in more detail if they have been shown to be related 202 
to immunity against the tumor or have possible prognostic meaning based on published research. 203 
 204 
Minor issues 205 
 206 
Information regarding the quality of the sample 207 
 208 
Information regarding the quality of the sample is crucial for interpreting the results of analysis and identifying any 209 
possible sources of bias. Unanimous consensus was reached about the relevance of including information regarding the 210 
quality of the sample and the evaluation of viability and preservation of cells in the report, including the type of 211 
technique used. This was considered mandatory information by the majority of the participants. These data may be 212 
derived from the evaluation of scatterplots, the evaluation of viable cells by using specific stains (propidium iodide, 213 
trypan blue, etc) or using other qualitative methods. Objective methods (propidium iodide or other stains) are 214 
preferable and results may be reported as percentage of viable cells or with a descriptive method. The technique used 215 
to assess the quality of the sample should preferably be specified in the final report. 216 
 217 
Gating strategies 218 
 219 
Although gating strategy used may be considered unnecessary information for clinicians and owners, this piece of 220 
information could be of use for specialists in order to better interpret results and for second opinions. Consensus was 221 
reached in considering it as relevant information to be possibly included in an FC report but no consensus was reached 222 
about the level of recommendation. 223 
 224 
Dot plot images 225 
 226 
Attaching images of dot plots to final reports could be of some use to other specialists to better understand gating 227 
strategies. However, they may be of limited use and difficult to interpret for most users (clinicians and pet owners) and 228 
may lead to potential misinterpretation. In addition, the choice of plots (histogram vs. dot vs. tridimensional) is not 229 
standardized and the results of all the antibodies used are not easily summarized in a few images. The routine inclusion 230 
of dot plots in a final report was not favored. Images or preferably. fcs files should be kept and can be provided upon 231 
request. 232 
 233 
Reporting absolute numbers 234 
 235 
Reporting absolute numbers of leukocyte subpopulations may be done by directly counting cells with the flow 236 
cytometer or by calculating them from flow cytometric percentages and complete blood count (CBC) data. Reporting 237 
absolute numbers could be useful mainly in blood, while they are probably of limited importance in bone marrow and 238 
lymph node aspirates in which relative percentages (out of CD45 positive cells or total cells) are much more important. 239 
When absolute numbers are reported, laboratory specific reference intervals should be provided. 240 
 241 
Cutoff value 242 
 243 
The cutoff value for considering a neoplastic population positive or negative for a specific antibody is another important 244 
issue. The determination of the percentage of positive neoplastic cells depends on the appropriate negative controls 245 
used and may be variable among observers. The use of isotype or fluorescence minus one (FMO) controls is strongly 246 
encouraged to correctly define background staining and fluorescence spillover. An internal control (biological 247 
comparison control) i.e. a negative population of cells from residual or non-neoplastic cells, is also mandatory to 248 
correctly define a cutoff value. However, for the sake of clarity, the results of controls should not be included in the final 249 
report. Some authors [13] suggested 20–30% as the lower limit to define a population as positive to a specific antigen 250 
but this value has been reconsidered in human medicine. Other authors reported positivity as <10% of cells = low, 10–251 
50% intermediate, >50% = high. No consensus was reached about a cutoff percentage value to define a cell population 252 
as positive, even though the majority of participants identified 20–30% as an acceptable value. The cutoff of positivity 253 
may depend upon the tissue analyzed (lymph node vs. peripheral blood vs. bone marrow) and the antigen investigated. 254 
The issue of controls and cut-off values was considered a crucial issue but beyond the scope of the present consensus 255 
paper (reporting flow cytometry results). Owing to its critical importance, this issue will be the focus of a future 256 
consensus document of the ECLN. Regarding this article, consensus was reached about the need to include appropriate 257 
controls in the flow cytometric procedure, but inclusion of the control results in the final report is not encouraged. 258 
Reporting quantitative antigen expression 259 
 260 
This may be useful for common lineage antigens (CD45, CD44, CD18) or activation antigens (Ki67, MHC II) and may 261 
provide information about maturation status, aberrant expression, or prognosis. In dogs, common lineage antigens 262 
have been reported to show different expression intensities in hematopoietic subsets and different maturation and 263 
activation stages [14, 15]. MHC II has been reported to be associated with prognosis in canine B cell lymphoma [16]. 264 
Ki67 has been reported to be useful in differentiating low and high grade lymphomas [17]. Quantitative aberrancies 265 
have been reported in different lymphoma subtypes [18]. Reporting intensities of antigen expression may be useful for 266 
markers with possible prognostic significance or for those expressed differently than expected. 267 
 268 
Quantitative expression is generally reported categorically as bright or dim but this may be subjective and poorly 269 
repeatable. Some authors reported antigen expression as bright or dim when a difference of at least 15% in 270 
fluorescence channels was present in the neoplastic population compared to the residual population of the same 271 
lineage [18]. This method is repeatable among different laboratories but it is quite complicated and it requires a clear 272 
identification of non-neoplastic residual cells of the same phenotype. Other authors [16] compared Mean Fluorescence 273 
Index (MFI) of a specific antigen (MHC II) in neoplastic cells to that derived from a cohort of neoplastic cases; expression 274 
was reported as “dim” if MFI was lower than the 15th percentile of all MFI calculated from a large series of canine 275 
lymphomas. This method is probably easier but it requires a different specific standardization from each laboratory to 276 
define the adequate cutoff value for fluorescence and a large caseload to calculate appropriate reference values. In 277 
addition, the expression of some antigens could be compared with those of a non-neoplastic reference population 278 
clearly identifiable in the sample (such as neutrophils in peripheral blood) [14]. This method is easy to perform and does 279 
not require any specific standardization but it is quite subjective and it is based on the assumption that antigen 280 
expression remains constant in the reference population. Finally, antigen expression could be accurately quantitated 281 
using a curve with calibrated beads but this method is expensive and difficult to apply to clinical/diagnostic conditions. 282 
 283 
In human medicine, the issue of antigen expression is also crucial. Intensity of staining for some antigens may be 284 
expressed as bright, dim, or negative, and according to their distribution as heterogeneous or homogeneous. Some 285 
authors also suggest possible reporting of expression as weak or strong. Strong refers to unequivocal positivity (not 286 
necessarily to bright expression) [8]. Other authors suggest defining intensity of some antigens as low (when the 287 
histogram is significantly different but not easily separable from the negative control), middle (when the fluorescence 288 
peak is contiguous to the negative control but completely distinguishable from it), or high (when the fluorescence peak 289 
is two or three logarithmic decades higher than the negative control) [19]. Some antigens (such as ZAP-70 protein in 290 
human CLL) are reported comparing MFI of neoplastic cells to those of T cells in the same sample. This method is 291 
reported as easy to perform and optimal for accurately predicting outcome in CLL [20]. 292 
 293 
Because no definitive rules on the best way to report fluorescence intensity of antigens in FC reports of canine 294 
hematopoietic neoplasms have been generated to date, some recommendations are proposed: (1) antigen expression 295 
may be preferentially expressed as dim or bright and data on distribution of the antigen (homogeneous vs. 296 
heterogeneous) should be provided only if useful to discriminate between normal and neoplastic populations, to define 297 
subtype, to track infiltration/residual disease of neoplastic cells (when quantitative aberrant patterns are present) or to 298 
define prognosis; (2) when this quantitation is reported, the definition of neoplastic cells as dim or bright should be well 299 
standardized for each antigen and consistent with methods from published references; 3) in the absence of specific 300 
published references, the criteria used for defining quantitative antigen expression (dim vs. bright) could be provided in 301 
supplementary notes, together with the putative biological meaning; (4) when possible, quantitative expression of 302 
antigens should be compared with the closest normal hemic population; (5) quantitative findings that are irrelevant to 303 
clinical importance (i.e., not involving staging, prognosis, minimal residual disease, etc.) should be avoided; (6) data 304 
regarding in-progress studies should be omitted from the diagnostic report until they complete the peer-review and 305 
publication process. If necessary, references of published FC entities could be provided in the notes. 306 
 307 
Reporting aberrant patterns 308 
 309 
Qualitatively and or quantitatively aberrant patterns have been reported in several studies in different lymphoma 310 
subtypes in dogs [18, 21, 22] and may differ from the human counterparts. Their importance is far from completely 311 
elucidated but, in some cases, specific aberrant patterns may be useful to define specific subtypes, or to accurately 312 
track neoplastic infiltration in tissues and to detect minimal residual disease. In particular, a specific subtype of canine 313 
lymphoma with peculiar aberrant patterns different from its human counterpart, T zone lymphoma, is well recognized. 314 
This indolent T cell lymphoma subtype is not uncommon in the dog, in contrast to people, and exhibits a characteristic 315 
decreased expression of CD45 and frequently the concurrent aberrant expression of CD21 [1, 2]. The likelihood of 316 
detecting an aberrant phenotype is linked to the number of antibodies used and to the type of labeling and analysis 317 
performed (mono- vs. multi-color). Although evidence of the prognostic role of aberrancies in canine hematopoietic 318 
neoplasms is largely still lacking, it is likely that some specific aberrancies could have a correlation with biological 319 
behavior, similar to what has been reported in human medicine [23-28]. Clinicians are often interested in the presence 320 
of aberrant patterns, although they may tend to overestimate their meaning. The report of percentages of positive cells 321 
alone may miss the detection of specific aberrant patterns. The presence of a specific aberrant pattern in neoplastic 322 
cells should be indicated in the descriptive part of the report if it may be useful to document the infiltration of 323 
neoplastic cells in organs, to monitor therapy and minimal residual disease, to facilitate the early detection of relapse or 324 
if it may have a specific biological meaning (prognosis, response to therapy, etc). 325 
 326 
Adding a statement to the descriptive part of the report regarding possible FC marker(s) to check infiltration or monitor 327 
follow-up and detect relapse may be helpful and should be encouraged. These markers may include single labeling (for 328 
instance CD34+ cells in acute leukemias), multiple labeling (e.g., CD3+ CD45− cells for T zone lymphomas) or 329 
fluorescence and morphological aspects together (e.g., large CD21+ cells for DLBCL). 330 
 331 
Integration of other clinical data 332 
 333 
Moving toward an integrated report including hematologic, cytologic, histopathologic, immunohistochemical, and 334 
molecular biologic data is a major goal. However, the availability of results will influence the possibility of a report 335 
integrating all of the laboratory results. An integrated report including hematologic, cytologic, and FC results while 336 
waiting for results of other ancillary techniques may be a good compromise and is encouraged. 337 
 338 
Proposal of a Possible Template for Reporting FC Results 339 
 340 
According to the previously discussed issues, the proposed report for FC immunophenotyping of canine hematopoietic 341 
neoplasms should include several sections. 342 
 343 
1. Laboratory identification  344 
2. Patient identification  345 
3. Type and quality of the sample(s)  346 
4. Sample preparation and staining  347 
5. Percentages of positive cells  348 
6. Descriptive report  349 
7. Diagnosis and interpretation  350 
8. Comments and references  351 
9. Signatures 352 
 353 
For each section some mandatory, recommended and additional information was identified (Table 1). 354 
 355 
Conclusion 356 
 357 
The present article is a first step toward standardization of the flow cytometric approach for canine hematopoietic 358 
neoplasms among different institutions and countries. It should help to provide a more accurate report to users and 359 
support the use of flow cytometric immunophenotyping in the diagnostic algorithm for canine lymphoma and leukemia. 360 
The creation of consensus documents on other important issues, including preprocessing, instrument standardization 361 
and maintenance, controls and cut-offs, and suggested antibody panels is an ongoing process for the flow cytometry 362 
panel of the ECLN. 363 
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  450 
Table 1. Results of the consensus survey among ECLN flow cytometry panel on recommended information in different 451 
sections of a canine hematopoietic neoplasm flow cytometry report. Each piece of information was considered 452 
“relevant” if more than 75% of responders classified it as “mandatory”, “recommended” or “additional". 453 
Recommendations for each piece of information reflect the category at which > 50% of responders concurred. Failure 454 
to achieve these thresholds resulted in a designation of no consensus. Relevancy or recommendation scores of 100% 455 
are in bold. 456 
  Percentage of agreement (%) Relevance 
of information 
Recommendation 
  mandatory recommended additional irrelevant 
Laboratory 
identification 
Name of the 
laboratory 
100 0 0 0 Relevant Mandatory 
 Postal address 53 27 13 7 Relevant Mandatory 
 Telephone number 60 40 0 0 Relevant Mandatory 
 e-mail contact 60 40 0 0 Relevant Mandatory 
 Web page 13 47 27 13 Relevant No consensus 
 Authorization 
number or licenses 
20 40 27 13 Relevant No consensus 
        
Patient 
identification 
Date of the report 93 7 0 0 Relevant Mandatory 
 Date of analysis 64 36 0 0 Relevant Mandatory 
 Internal ID code 60 40 0 0 Relevant Mandatory 
 Owner's name 80 13 7 0 Relevant Mandatory 
 Referring physician 
name and 
institution 
53 40 7 0 Relevant Mandatory 
 Species 93 7 0 0 Relevant Mandatory 
 Breed 67 33 0 0 Relevant Mandatory 
 Gender 60 40 0 0 Relevant Mandatory 
 Age 73 27 0 0 Relevant Mandatory 
 Patient name 60 27 7 7 Relevant Mandatory 
 Previous therapy 33 13 54 0 Relevant Additional 
 Clinical history 40 20 40 0 Relevant No consensus 
 Other laboratory 
results (CBC, Diff) 
27 40 33 0 Relevant No consensus 
        
Type and 
quality of the 
sample 
Type of tissue(s) 93 7 0 0 Relevant Mandatory 
 Type of sample 
(aspirate, biopsy, 
blood, fluid, etc) 
73 27 0 0 Relevant Mandatory 
 Quality of the 
sample (estimated) 
73 27 0 0 Relevant Mandatory 
 Sampling data 73 27 0 0 Relevant Mandatory 
 Percentage of 
viable cells 
26 60 13 0 Relevant Recommended 
 Technique used for 
viability estimation 
13 73 13 0 Relevant Recommended 
 Specimen number 33 53 13 0 Relevant Recommended 
        
Cell 
preparation 
and staining 
Antibodies used 87 13 0 0 Relevant Mandatory 
 Cell preparation 
(whole sample, 
scraping, Ficoll, 
RBC lysis) 
20 53 27 0 Relevant Recommended 
 Antibody clone 0 13 60 27 No consensus Additional 
 Fluorochrome 
combination 
0 13 60 27 No consensus Additional 
 Composition of 
tubes 
0 7 73 20 Relevant Additional 
 Type of controls 0 27 60 13 Relevant Additional 
 Instrumentation 0 13 53 33 No consensus Additional 
 Expected 
positivities for each 
antibody 
13 33 40 13 Relevant No consensus 
        
Descriptive 
report 
Qualitative 
description of 
immunophenotype 
of cells of interest 
78 14 7 0 Relevant Mandatory 
 Comment on 
quantitative 
expression of 
relevant markers 
53 27 20 0 Relevant Mandatory 
 Aberrant patterns 67 33 0 0 Relevant Mandatory 
 Information about 
staging 
7 80 13 0 Relevant Recommended 
 Information about 
residual cells 
0 73 27 0 Relevant Recommended 
 Qualitatitive 
description of 
scatter aspects of 
cells of interest 
47 40 13 0 Relevant No consensus 
        
Percentage of 
positive cells 
Percentage of 
positive cells in 
gated population 
53 47 0 0 Relevant Mandatory 
 Percentage of 
positive cells in 
whole population 
29 57 7 7 Relevant Recommended 
 Intensity of staining 
(dim vs bright, 
homogeneous) 
20 60 20 0 Relevant Recommended 
 Absolute count on 
positive cells (in 
peripheral blood 
only) 
20 53 20 13 Relevant Recommended 
 CD4/CD8 ratio 7 27 53 13 Relevant Additional 
 Representation of 
histogram/plot 
7 20 60 13 Relevant Additional 
 Fluorescence index 
(quantitative) 
0 40 47 13 Relevant No consensus 
 Gating procedure 13 33 33 20 Relevant No consensus 
 Reference intervals 
for each antigen 
7 40 47 7 Relevant No consensus 
        
Diagnosis and 
interpretation 
Diagnosis of 
immunophenotype 
100 0 0 0 Relevant Mandatory 
 Lymphoma subtype 
(tentative) 
53 40 7 0 Relevant Mandatory 
 Stage 20 60 7 13 Relevant Recommended 
 Suggested FC 
markers for 
monitoring stage 
and MRD 
0 67 33 0 Relevant Recommended 
 Possible 
prognostic 
factors 
27 53 20 0 Relevant Recommended 
 Grade (high vs 
low) (tentative) 
40 40 20 0 Relevant No consensus 
        
Comments Clinical and 
outcome 
information 
0 64 36 0 Relevant Recommended 
 Additional tests 
suggested 
0 53 40 7 Relevant Recommended 
 References 0 47 53 0 Relevant Additional 
        
Signatures Party 
responsible 
for the service 
73 20 7 0 Relevant Mandatory 
 Flow cytometrist 33 47 20 0 Relevant No consensus 
 457 
